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ABSTRACT 
Several types of cancer have been linked to the Epidermal Growth Factor Receptor 
(EGFR) family of tyrosine kinases. An EGFR homolog in Drosophila, dEGFR, was found 
to be inhibited by a protein called Kekkon1 (Kek1). Kek1 is a member of the LIG super 
family, meaning it contains both Leucine-rich repeats (LRRs) and Immunoglobulin (Ig) 
domains. Based on structural similarities it was hypothesized that members of the human 
LIG family could interact with the human members of the EGFR family. An ELEXIS 
interaction assay was used to test interactions between human LIGs and the EGFRs 
(ErbB1,2,4). Interactions between different human LIGs were also tested. Binding 
between the human LIGs and receptors could indicate the potential use of LIGs as a 
cancer therapeutic. 
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INTRODUCTION 
The human nervous system serves as a method for transmitting information throughout 
the body. As neural circuits develop, axons extend through the body and innervate target 
cells. This process of branching and neural development requires a series of receptors 
and their ligands to organize and regulate axonal extension. A family of molecules, known 
as LIGs, has been found to promote neural growth by interacting with tyrosine receptor 
kinases (Mandai et al. 2009). 
 
Structural Features of LIG Proteins 
LIGs are transmembrane proteins that contain both leucine-rich repeats (LRRs) and 
immunoglobulin domains (Ig domain). These two sequences are 
commonly found in proteins, but it rare to find both in a single protein. 
LRRs have been found to promote interaction between LRR proteins 
(Aylwin and Ramnik 2011).  Figure 1 shows the structure of a general 
LIG protein with its LRRs and Ig-like domain.  
 
Leucine Rich Repeats 
The leucine-rich repeat is a common structural motif that is 
characterized by 20-30 amino acids that have a conserved pattern  
of eleven residues primarily comprised of leucines - LxxLxLxxNxL, 
where x is any residue, L is leucine,and N is asparagine (Bella et al. 2008; de Wit et al. 
2011). This area forms a β-strand and a loop, and this connects back to the C-terminus 
(Kajava 1998). These repeats typically come in tandem with as few as three and up to as 
	
Figure 1. Structure of 
a LIG protein. The red 
trapezoids contains 
the LRRs and the grey 
loop contains the Ig-
like domain. 
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many as 30 repeats, which are then flanked at the N and C terminus by cysteine-rich 
regions (Kobe and Deisenhofer 1994; Kajava 1998; Bella et al. 2008; de Wit et al. 2011). 
The β-strands of each repeat together form a β-sheet, creating a horseshoe-shaped 
structure that acts as a binding site for diverse protein-protein interactions, including 
between other LRR regions.  The β-sheet or concave side of the horseshoe shaped 
typically serves as the ligand-binding site.  Proteins in the LRR family have been found to 
be involved in diverse events, including cell signaling pathways, hormone-receptor 
interactions, and the connectivity of neural circuits (de Wit et al. 2011). 
 
Immunoglobulin domains 
In contrast to LRRs, Immunoglobulin (Ig) domains were defined initially as specific 
conserved sequences found in antibodies or immunoglobulins. Ig domains are found in a 
large number of proteins, broadly defined as the Ig Superfamily.  These domains are 
composed of ~100 amino acids in which two sheets of antiparallel β-strands linked by 
loops create a sandwich-like structure (Williams and Barclay 1988). The loops are 
connected through disulfide bridges (Williams and Barclay 1988). Similar to interactions 
between LRRs, Ig domains have also been found to be involved in binding with other 
axonal proteins with Ig domains (Brümmendorf and Rathjen 1996). Taken together these 
observations support the notion that in addition to interacting with other molecules, LIG 
proteins may in fact interact with each other.  
 
The LIG superfamily can be divided into subfamilies based on their structural organization 
and sequence relationships (Homma et al. 2009). This project focused on two different 
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subfamilies of LIGs known as the LRITs and NLRRs (Ishii et al., 1996; Sheikh et al., 2016; 
Sarria et al. 2018; Ueno et al. 2018). There are three proteins in the LRIT family: LRIT1, 
LRIT2, and LRIT3 (Ueno et al. 2018). LRIT1 contains 7 LRRs and 1 Ig-like domain, and 
has been identified as a retinal transmembrane protein that regulates light adaptation and 
daylight vision (Sarria et al. 2018; Ueno et al. 2018). LRIT2 contains 6 LRRs and 1 Ig-like 
domain, and its exact function is still being studied. LRIT3 contains 6 LRRs and 1 Ig-like 
domain, and was found to interact with the fibroblast growth-factor receptor (FGFR) (Kim 
et al. 2012). Overexpression of the FGFRs has been linked to cancer, and LRIT3 was 
found to regulate the FGFR1 signaling pathway by facilitating the exit of FGFR1 from the 
ER (Kim et al. 2012). Like the LRITs, there are three members of the NLRR family 
(NLRR1,2,3), however unlike the LRITs, which include a fibronectin domain in their 
extracellular region, the NLRRs only include the LRRs and an Ig domain (Ishii et al., 1996; 
Sheikh et al., 2016; Sarria et al. 2018; Ueno et al. 2018).  Currently, the NLRRs have 
been implicated in neuroblastoma, but significantly less is known about this LIG 
subfamily. 
 
Despite being structurally similar to each other, current evidence across the LIG family 
suggests family members can serve a variety of distinct molecular and cellular functions, 
including roles in receptor tyrosine kinase (RTK) signaling and synaptic signaling. The 
focus of this project will be on specific LIGs and their ability to interact with receptor 
tyrosine kinases, or RTKs. Specifically, this project will look at interactions between 
members of the human LIG family and a family of RTKs known as the Epidermal Growth 
Factor Receptors (EGFRs). 
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Epidermal Growth Factor Receptors 
 Epidermal Growth Factor Receptors, or EGFR/ErbB, are a family of human 
receptor tyrosine kinases that induce cell differentiation and proliferation (Voldborg et al. 
1997). There are four ErbB receptors that have been found in humans – 
EGFR/ErbB1/HER1, ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4 (Fig. 2). The ErbB 
receptors are known for their role in cancer proliferation, including neuroblastoma and 
breast cancer (Zhang et al. 2007). The ErbB receptors are 
composed of an intracellular domain, a short 
transmembrane domain, and an extracellular domain with 
ligand-binding activity (Normanno et al. 2006). The 
extracellular region contains four subdomains numbered I-
IV. Ligand binding takes place in the sequence related 
subdomains I and III. In contrast, domains II and IV are 
involved in inter-receptor interactions. The intracellular 
domain is highly conserved across the ErbB receptors and is composed of a tyrosine 
kinase domain and the C-terminal tail (Normanno et al. 2006). The structure of the ErbB 
receptors allows the ligand binding to induce an intracellular response. 
 ErbB receptors can be activated by a variety of ligands and ErbB-specific growth 
factors. There are three groups of ligands that bind the ErbB receptors: epidermal growth 
factor (EGF), amphiregulin (AR), and transforming growth factor alpha. Not all of the ErbB 
receptors have the same domains; ErbB2 does not have the ability to bind ligands, so its 
main purpose is to dimerize with the other ErbB receptors. ErbB3 does not have an 
Figure 2. ErbB family. 
Domains I and III of ErbB2 
are blue to indicate they do 
not bind ligands. The 
intracellular domain of ErbB3 
is black to indicate that there 
is no kinase activity. 
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intracellular tyrosine kinase domain (Normanno et al. 2006). The structure of each ErbB 
receptor can be seen in Figure 2. 
 Upon binding a ligand, ErbB receptors will dimerize in order to activate their 
intracellular kinase domain. The tyrosine residues on the receptor are phosphorylated to 
facilitate protein binding, and the protein binding 
induces a cellular response (Fig. 3). 
 Ligand binding induces a conformational change 
in the ErbB receptors that allows the II and IV regions 
of the receptors to dimerize using a dimerization loop 
(Lemmon et al. 2014). Until the receptor binds a ligand 
the dimerization loop is hidden and the receptors are 
predominantly monomeric.    
 
Previous work from the Duffy lab had demonstrated that the Drosophila EGFR 
(dEGFR) is negatively regulated by the LIG Kekkon1 (Kek1) through direct binding 
(Alvardo et al. 2004).  With this interaction in mind, the goal of this project was to assess 
if specific human LIGs interact with members of the human EGFR family. 
 
Figure 3. ErbB dimerization 
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MATERIALS AND METHODS 
 
Generating LIG Constructs for Bait and Prey Proteins 
 For the ELEXIS interaction assay secreted variants of the human LIGs that were 
tagged had to be generated. Gateway cloning was used for all cloning steps. Two types 
of C-terminal fusions were generated, fusions to Alkaline Phosphatase represented the 
Bait constructs, while fusions Fc represented the Prey constructs.  LIG constructs, 
including LRIT1, LRIT2, LRIT3, TrkB, and TrkC, were initially designed in silico using 
Gene Construction Kit (GCK) software.  First, the extracellular region for each LIG was 
predicted using the online transmembrane prediction software CCTOP 
(http://cctop.enzim.ttk.mta.hu).   Based on this a 5’ attB1.1 primer containing the start 
codon and a 3’ attB2.1 primer corresponding to the region prior to the transmembrane 
domain were designed for LRIT1, LRIT2, LRIT3, TrkB, and TrkC.  Constructs and primers 
for NLRR1,2,3 had been previously designed in the lab. The appropriate primer pairs 
were then used in PCR reactions using the corresponding human LIG cDNA as a 
template, to amplify the portion of the open reading frame representing the sLIG variant.  
The PCR fragments were digested and amplified by PCR.  PCR fragments were then 
analyzed by gel electrophoresis and purified using Qiagen gel extraction kits. PCR 
fragments were then subcloned by a BP GatewayTM (Invitrogen) reaction to form an entry 
clone, or pENTR.  These pENTR constructs were sequenced (Eton BioScience) and 
confirmed using the Sequencher analysis program.  Correct pENTR clones were then 
subjected to a LR GatewayTM (Invitrogen) reaction to shuttle the human LIG extracellular 
coding sequence into the pIB-attB-AP or pIB-attB-Fc vector to produce an expression 
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clone with the appropriate sLIG variant and the correct tag.  Standard molecular 
techniques were used to transform and recover plasmids.  Expression clones were 
confirmed by 5’ and 3’ sequenced (Eton BioScience) and confirmed using the 
Sequencher analysis program. Cloning procedure is diagrammed below in Figure 4. 
 
 
 
 
 
Transfection of LIG Expression Clones 
 To produce all sLIGs, expression constructs were transiently expressed in 
Drosophila S3 cells.  S3 Drosophila cells were thawed and maintained as described by 
Cherbas, et al (Cherbas, 1998). To transfect cells with the DNA constructs, cells were 
first counted to 3.125 x 106 cells/ml and 1.6 ml of cells were seeded in 6-well cell culture 
plates.  The seeded cells were incubated overnight under normal growth conditions of 
25°C without CO2 to obtain 100% confluence. The cells were then transfected with the 
respective LIG pIB responder constructs (NLRR2-AP, NLRR3-AP, TrkB-Fc, TrkC-Fc, 
LINGO1-AP, and LINX-AP) following the protocol described by Wojtowicz et al. 
(Wojtowicz, et al. 2007).   
After incubating the transiently transfected cells for 1 week, the media supernatant 
was collected and gently centrifuged to pellet any suspended cells.  The supernatant was 
 
Figure 4. pIB system used in transfection with AP or Fc-tagged LIG constructs for protein expression. 
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collected, filtered with a 0.22 μm PES filter, vortexed, and aliquoted into eppendorf tubes.  
Each protein sample was then stored at 4° C.  
 
Bait Assessment 
 Each AP bait sample was assessed by hPLAP enzymatic activity against an 
hPLAP enzymatic standard curve, previously generated by the Duffy lab. The standard 
curve was created by making a dilution series of 100 U/L, 75 U/L, 50 U/L, 25 U/L, 10 U/L 
hPLAP in cell culture supernatant.  The activity of each AP bait sample was assessed 
against the standard curve by comparing a high concentration, 75 μL, and a low 
concentration, 20 μL. The activity of each sample at each concentration against the 
activity of cell culture supernatant was assayed by adding an equal volume of PNPP 
(Pierce) substrate to both the hPLAP standards and AP-tagged protein samples and 
tracked every minute over a 20 minute time frame at 405 nm using a Victor3 plate reader 
and Wallac software.  The velocities of each AP bait sample concentration over 10 
minutes were converted into a standard curve assessing hPLAP velocity vs. hPLAP 
concentration (U/L) that was used to quantify the hPLAP concentration in each AP bait 
sample. These velocities were used to quantify and normalize the AP-tagged protein 
samples against the hPLAP standard curve. 
 
Prey Assessment 
 Each Fc prey sample was assessed using an Fc ELISA (Syd Labs) against an Fc 
standard (Jackson Immuno). An Fc standard was tested at 5 ng/mL, 0.313 ng/mL, and 0 
ng/mL. The Fc samples (TrkB-Fc and TrkC-Fc) were each tested at two dilutions, 1:250 
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and 1:750. An equal amount of TMB Ultra (Thermo) was added to each well and was 
tracked over a 13 minute time frame at 590 nm using a Victor3 plate reader and Wallac 
software. The velocities of each sample were compared to the HRP standard curve in 
order to quantify the protein concentration in each sample. 
 
Protein Interactions 
 To determine if AP-tagged LIGs 
interact with Fc-tagged ErbB family of 
receptors or the TrkB,C-Fc receptors, 
an ELISA based screening assay 
described by Wojtowicz et al. was used 
(Wojtowicz, et al. 2007). This enzyme 
linked extracellular interaction assay, or 
ELEXIS, was set up following Figure 5 and is described in detail below. 
Each interaction well on a Medisorp plate was incubated with a mixture of 3 μg/mL 
Ms-anti-AP (8B6.18 Thermo) in 1x PBS (10 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl, 
and 137 mM NaCl) overnight at 4° C on a rocking platform.  Wells were washed 4x1min 
with 300 μl of wash buffer PBST (1x PBS and 0.05% Tween20) at room temperature on 
a rocking platform.  400 μl of Casein block solution (2.25% Casein in 1x PBS) was added 
to each well and incubated for 1.5 hours at room temperature on a rocking platform.  Each 
interaction reaction was generated during the blocking incubation period and contained 
0.5 pmol of each Fc-tagged interacting prey sample, 0.45 pmol of the AP bait sample, a 
final concentration of 1 μg/mL of the HRP conjugated Ms-anti-Fc detection antibody, and 
 
Figure 5. Structure of an ELEXIS assay. 
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supernatant to a total volume of 50 μL. The block solution was removed and the 
interaction mix was added into each well, the plate covered with tinfoil and incubated for 
4 hours at room temperature on a rocking platform.  After the incubation period wells were 
washed 4x1 min with 300 μl of PBST at room temperature on a rocking platform protected 
from light. The presence or absence of an interaction was assessed by adding 100 μL of 
1-Step TMB Ultra HRP Substrate (Pierce) to each well. Wells were then tracked at 590nm 
every 5 minutes for 25 minutes at room temperature using a Victor3 plate reader and 
Wallac software.  The reactions in each well were stopped with 100 μL of 1 M Phosphoric 
Acid (H3PO4) stop solution and the endpoint absorbance was detected at 450 nm.  Each 
protein interaction was compared to the positive control interaction between sKek1-AP 
and sdEGFR-Fc, with the negative control sKek2-AP and sdEGFR-Fc, which fails to 
exhibit an interaction. Background binding for both the Bait and Prey were assessed by 
comparing the interaction to both AP-tagged bait with supernatant and Fc-tagged prey 
with supernatant.  Relative interaction signals were generated by the following formula:  
((Bait•Prey abs.) – Prey•Supt. abs.))/ (Bait•Supt. abs.).    
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RESULTS 
 
As noted in the introduction, Kek1 binds directly to the Drosophila EGFR. Recent 
work in the Duffy lab has recently demonstrated this interaction can be recapitulated using 
secreted versions of the molecules in the ELEXIS assay developed by Wojtowicz et al. 
(Wojtowicz, et al. 2007). Using this assay, interactions between human LIGs and the 
EGFR family, as well as between human LIGs were analyzed. 
 
Generating Bait and Prey sLIG variant constructs: 
To test for interactions using the ELEXIS assay, prey and bait constructs encoding 
secreted versions of the human LIGs and EGFR family members were generated. Fc-
tagged prey constructs for ErbB1, 2, 3, and 4 had previously been generated by A. 
Putnam.  In addition, the LIGs, TrkB and TrkC, which are also RTKs due to the presence 
on their intracellular kinase domains, were also tagged with Fc and used as preys.  In 
contrast, expression constructs encoding the human LIGs, LRIT1, LRIT2, LRIT3, NLRR2, 
and NLRR3 were initiated.  For NLRR2 and 3 both AP and Fc expression constructs were 
generated, while the those for LRIT1,2 and 3 are currently in progress. 
 
Protein Expression and Quantification 
 Once the expression constructs were generated, protein expression for the tagged 
Baits and Preys was performed as described in the materials and methods. Briefly, 
expression clones were transiently transfected into S3 Drosophila cells, supernatants 
recovered and assessed either for AP activity (Baits) or the presence of the Fc tag 
(Preys).  
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Bait – AP tagged LIG protein concentration was assessed using an AP enzymatic 
assay. The assay used PNPP substrate and AP-tagged LIGs to test the absorbance of a 
known volume of the LIGs. The absorbance of the 
samples was compared to an hPLAP standard curve 
to determine the concentration of the AP-tagged LIG. 
Figure 6 shows a photograph of the AP-enzymatic 
test plate. Figure 7 is a graph of the hPLAP standard 
absorbance. In Figure 8 the absorbance of each AP-
tagged LIG was graphed comparing absorbance over 
time. Using this data, it was determined that the concentration of sLINX-AP was 893.0 
μU/μL and the concentration of sLINGO1 was 64.0 μU/ μL. Based on the absorbances 
for sNLRR2 and sNLRR3 they did not appear to express enough protein to be quantified. 
 
 
 
 
 
 
 
 
  
Figure 6. Bait quantification. Photo image 
of the 96 well plate used for AP-tagged 
protein quantification. Rows 1 and 3 
contain experimental samples, while rows 
2 and 4 contain AP standards, all at low 
and high concentration, respectively.  
Figure 7. hPLAP standard curves at 10 U/L and 100 U/L over 10 
minutes. 
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Prey – Fc tagged LIGs (sTrkB-Fc and sTrkC-Fc) were quantified using an Fc-ELISA. 
The assay used a coating and detection antibody solution (Syd 
Labs) to anchor and detect the Fc-tagged proteins and an Fc-
standard (Jackson Immuno) to compare the sample absorbance 
to a known value as detailed in the Materials and Methods. 
dEGFR-Fc was also run as a control (quantified previously in the 
Duffy lab). After adding the TMB Ultra, absorbance of the 
samples was measured at 590 nm every minute for 13 minutes. 
Figure 9 is a photo of the ELISA plate after 13 minutes. The 
data for the standards can be seen in Figure 10 and the 
experimental data for sTrkB-Fc and sTrkC-Fc can be seen in 
Figure 11. The reaction was stopped after 13 minutes by the 
Figure 8. Activity plot over 10 minutes for sLINX-AP, sNLRR2-AP, 
sNLRR3-AP, and LINGO1-AP. sLINGO1-AP is at a higher concentration 
than the other samples. 
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Figure 9. Photo of Fc-
ELISA plate after 13 
minutes. The left column 
contains the high and low 
standard in triplicate. The 
right column contains a 
1:250 and 1:750 dilution of 
TrkB-Fc, TrkC-Fc, and 
dEGFR-Fc. 
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addition of 1M H3PO4 (Sigma). Based on the ELISA assessment of the Prey proteins, 
sTrkB-Fc had a final concentration of 4.0 ng/µL, sTrkC-Fc had a final concentration of 
4.6 ng/µL, and sdEGFR-Fc had a final concentration of 3.8 ng/µL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Absorbance over time for a high and low concentration of the 
HRP Fc-Standard. 
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Figure 11. Absorbance over time for Fc-tagged LIGs. 
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Testing LIG - EGFR Family and LIG - LIG Interactions 
 While the sLRIT1,2,3 clones were not complete and expression of the sNLRR1,2 
AP tagged clones was not recovered, expression of sTRKB-Fc, sTRKC-Fc and sLINX-
AP were obtained as described above.  These along with sAMIGO1-AP were tested in an 
ELEXIS assay to determine their binding properties. Specifically, sLINX-AP and 
sAMIGO1 were tested with the receptors sErbB1-Fc, sErbB2-Fc, sErbB4-Fc, sdEGFR-
Fc, and the LIGs/receptors TrkB-Fc, and sTrkC-Fc. The sKek1/sdEGFR interaction 
served as a positive control and sKek2/sdEGFR interactions served as a negative control. 
sKek1-AP, sKek2-AP, sAMIGO1-AP, sdEGFR-Fc, sErbB1-Fc, sErbB2-Fc, and sErbB4-
Fc were provided by Alex Putnam from the Duffy lab. Figure 12 is a photo of the ELEXIS 
plate after stopping the detection reaction.  
Figure 13 shows the extracellular protein-
protein interaction (ePPI) signal representing 
the fold interaction of each sample compared to 
their readings above the background (see 
materials and methods for description).  In the 
ELEXIS assay, the only combination that 
exhibited an interaction was the positive control 
of sKek1/sdEGFR.  In contrast, none of the other 
sLIG-sReceptor or sLIG-sLIG combinations 
resulted in a positive signal. 
 
 
Figure	 12.	 Photo	 of	 the	 ELEXIS	 assay.	
Yellow	 color	 indicates	 an	 interaction.	
Black	 wells	 were	 not	 used.	 Positive	
control	 in	 A1	 and	 negative	 control	 in	
B1.	
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DISCUSSION 
	
  Kek1 is known to bind to dEGFR in a variety of contexts including the 
ELEXIS assay.  In addition, previously published work reported that full-length LINX and 
AMIGO1 were able to bind to full length TrkC (Mandai et al. 2009). This led to the objective 
of this report to determine if an interaction between human LIGs and members of the 
EGFR family could be detected in the ELEXIS assay. 
In this report, data indicating that of four of the six LIGs that were transfected into 
Drosophila cells were successfully secreted, but only three, sLINX-AP, sTrkB-Fc, and 
sTrkC-Fc were in concentrations high enough to continue with the interaction assay. 
sLINGO1 would need to be concentrated or transfected again in order to produce enough 
product to test interactions. sNLRR2 and sNLRR3 did not produce quantifiable product 
Figure 13. sAMIGO1 and sLINX ePPI signals compared to the positive 
(sKek1/sdEGFR) and negative (sKek2/sdEGFR) controls. 
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after being transfected, and would need to be transfected again to obtain a usable 
concentration. 
 After the proteins were assessed, sLINX-AP and sAMIGO1-AP were run against 
sErbB1,2,4-Fc, sTrkB-Fc, and sTrkC-Fc. A positive and negative control were run on the 
same plate to ensure that the assay functioned as intended. The positive control gave 
high signal, ePPI of 61, while the negative control gave little to no signal. This confirmed 
that the assay format is functional. Little to no signal was detected for all of the other 
interactions, suggesting that, in this format, sLINX-AP and sAMIGO1-AP do not bind to 
sErbB1, sErbB2, sErbB3, sTrkB-Fc, or sTrkC-Fc.  While this initial screen did not uncover 
any interactions, it will be important to assess a number of key factors. The absence of 
any detectable interactions between the LIGs and receptors, could be for a number of 
reasons.   
First, it is possible that the lack of interaction between the AP-tagged sLIGs and 
Fc-tagged sReceptors was due to the proteins not folding properly because the 
transmembrane and intracellular domains were removed, or second that any such 
interactions require these regions as well.  Thirdly, while expression of the AP and Fc 
tags was detected, it is possible that proteolysis during expression resulted in separation 
of the tag from the Bait or Prey molecules.  To determine if proteolysis occurred, next 
steps would be to perform a Western blot to characterize if the tagged proteins are the 
expected sizes.  Finally, if positive controls could be established for either sLINX or 
sAMIGO1 or the sEGFR or Trk family members this would provide greater confidence 
that the absence of an interaction was not simply due to inappropriate folding. 
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